ABBV vs MGX · P/E 81, rev $16.99B vs rev $25.2M
AbbVie Inc (ABBV) versus Metagenomi, Inc. Common Stock (MGX) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
Metagenomi, Inc. Common Stock (MGX) is a biotechnology company listed on NASDAQ.
Latest reported ABBV revenue for 2026-06-30 was $16.99B. Net income was $3.61B. Revenue was up 13.3% from 2026-03-31 to 2026-06-30. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported MGX revenue for 2025-12-31 was $25.2M. Net income was -$87.9M. Revenue was down 51.8% from 2024-12-31 to 2025-12-31. MGX currently screens at market cap $44.4M.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. MGX currently screens at market cap $44.4M.
Not investment advice. Open the ABBV and MGX stock pages for the full models.
Not investment advice.